FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.

The new regimens developed over the last few years have led to an improvement in the treatment of advanced gastric cancer, and our previous experience confirmed the fact that the combination of etoposide, doxorubicin and cisplatin (EAP regimen) is an active treatment that leads to interesting comple...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajetta, E., Di Bartolomeo, M., Carnaghi, C., Buzzoni, R., Mariani, L., Gebbia, V., Comella, G., Pinotti, G., Ianniello, G., Schieppati, G., Bochicchio, A. M., Maiorino, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150127/
https://www.ncbi.nlm.nih.gov/pubmed/9569054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150127/
https://www.ncbi.nlm.nih.gov/pubmed/9569054

Ejemplares similares